EHA 2015

EHA 2015 highlights

Peter Goodwin - ecancer reporter

Here at the European Haematology Association meeting in Vienna we’ve been hearing about newly diagnosed acute myeloid leukaemia and how you can now go beyond chemotherapy with sorafenib to increase relapse free survival. For patients with relapsed or refractory chronic lymphocytic leukaemia there could now be an option with the drug venetoclax which targets BCL-2. This apparently has achieved deep responses, according to research from Australia.

In chronic myeloid leukaemia light has been thrown on whether and when you can discontinue TKI therapy. It seems to be that deep molecular responses are what you need to look for. And we have news from the United Kingdom about a mutation many of us have that can cause leukaemia, not in the young but usually in the old and dependent on the blood making environment.

So do stay with ecancer.tv here at the European Haematology Association in Vienna for expert interviews, round table discussions and all the latest news in haematology oncology.